Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 7/20 | 0.46 |
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30945310 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL35060 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL9331881 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL13788602 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL2805155 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL450913 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL23728804 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL21113607 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL22515370 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A | |
| SCHEMBL30062304 | 1.00 | TDP1 (0.49) | TDP1MAOAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137822-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | ABDERA THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12624038-B2 | Molecules and methods related to treatment of uncontrolled cellular proliferation | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4676538-A2 | BI-SPECIFIC ADAPTERS AND THEIR USE WITH UNIVERSAL CAR-T CELLS IN THE TREATMENT OF CAIX-EXPRESSING TUMORS | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250282876-A1 | STABLE Fc FRAGMENTS, CONJUGATES, COMPOSITIONS, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2025-09-11 | — | — | US | disclosed |
| US-20250255956-A1 | DUAL AND TRIPLE HAPTEN CONJUGATES, COMPOSITIONS, PROCESSES FOR MAKING, AND METHODS OF TREATMENT THEREWITH | PURDUE RESEARCH FOUNDATION | 2025-08-14 | — | — | US | disclosed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4577578-A1 | DLL3 BINDING MOLECULES AND USES THEREOF | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577250-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | Abdera Therapeutics Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025085647-A2 | FC FRAGMENTS, CONJUGATES, COMPOSITIONS, AND METHODS OF USE | KAMRA MOHINI (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4221756-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2023-08-09 | — | — | EP | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023080652-A1 | ANDROGEN RECEPTOR DEGRADERS FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AND USE THEREOF | AUTOTAC INC. (KR) | 2023-05-11 | — | — | WO | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| WO-2022175750-A1 | IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | Abdera Therapeutics Inc. (CA) | 2022-08-25 | — | — | WO | disclosed |
| US-20220251097-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2022-08-11 | — | — | US | disclosed |
| WO-2022138550-A1 | REAGENT FOR BLOOD VESSEL IMAGING | 国立大学法人群馬大学 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
| WO-2021022076-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255956-A1 | DUAL AND TRIPLE HAPTEN CONJUGATES, COMPOSITIONS, PROCESSES FOR MAKING, AND METHODS OF TREATMENT THEREWITH | HAVCR2, CD4, CD44 | TDP1 2404/4885MAOA 3926/4885MAOB 3627/4885 |
| US-20220251097-A1 | MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION | MKI67, BCL2, PCNA | TDP1 2146/4885MAOA 2464/4885MAOB 1943/4885 |
| US-12344675-B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | DLK1, CD2BP2, IGLV6-57 | TDP1 3937/4885MAOA 4868/4885MAOB 4866/4885 |
| US-20250282876-A1 | STABLE Fc FRAGMENTS, CONJUGATES, COMPOSITIONS, AND METHODS OF USE | FCGR3B, FCGR2A, FCGR1A | TDP1 3810/4885MAOA 3094/4885MAOB 3078/4885 |
| US-20260137822-A1 | MULTIVALENT IMMUNOCONJUGATES FOR TARGETED RADIOISOTOPE THERAPY | FCGR2A, FCGR3B, FCGR1A | TDP1 3013/4885MAOA 3937/4885MAOB 3900/4885 |
| US-12624038-B2 | Molecules and methods related to treatment of uncontrolled cellular proliferation | CCNC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MKI67 | TDP1 2948/4885MAOA 2273/4885MAOB 1827/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | TDP1 136/4885MAOA 3799/4885MAOB 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.